Non-Human Primate (NHP) Applications in Infectious Diseases

Are you currently facing challenges with long drug development cycles, a lack of clinically relevant data for your infectious disease research, or complex regulatory submissions? Creative Biolabs helps you accelerate drug discovery and develop highly effective vaccines and therapeutics by leveraging the power of NHP models. Our advanced preclinical platforms provide the essential translational data you need through robust disease modeling and comprehensive safety and efficacy evaluations.

The Power of NHP Models in Infectious Disease Research

NHP models provide essential translational data for the development of vaccines, antiviral therapies, and immunomodulatory drugs. Our platforms help bridge the gap between preclinical discovery and clinical success, providing a clear path forward for your therapeutic candidates.

Get a Quote

Overview of NHP Applications

What Are Our Research Areas?

Infectious diseases remain a significant global health threat, requiring continuous innovation in vaccine and antiviral development. Preclinical research is a critical step in this process, demanding robust models that accurately mimic human disease pathogenesis and immune responses. Non-human primates are essential in this area, offering a powerful platform for studying a wide range of viral infections, including emerging pathogens.

• Viral Pathogenesis & Vaccine Efficacy：Non-human primates (NHPs) are essential for studying viral pathogenesis and evaluating vaccine efficacy due to their close similarity to human immune systems. They enable detailed investigation of host–virus interactions, immune responses, and protective mechanisms under physiologically relevant conditions. NHP models are particularly valuable for assessing vaccine-induced immunity, durability, and safety prior to clinical trials.
• HIV, SARS-CoV-2, Emerging Viruses：NHP models play a critical role in the study of high-impact viral diseases such as HIV, SARS-CoV-2, and emerging pathogens. They support controlled infection and challenge studies, allowing evaluation of antiviral therapies, vaccine candidates, and immune protection in a translational setting. These models are widely recognized for generating data that informs both therapeutic development and public health responses.

Why Choose Us?

Creative Biolabs' NHP platforms offer a distinct advantage over conventional models due to:

• Genetic/Immunological Similarities: NHPs share a high degree of genetic and physiological homology with humans, leading to more accurate disease modeling.
• Clinical Translational Relevance: Data from NHP studies is often more predictive of human clinical outcomes, reducing the risk of failure in later-stage trials.
• Data Types Required for Regulatory Submissions: Our platforms are designed to generate the specific safety, PK/PD, and immunogenicity data required for regulatory approval.
• Complex Organ System Modeling: NHPs allow for the study of complex, systemic diseases that affect multiple organ systems, such as viral-associated CNS diseases.

Fig.1 Pediatric viral disease models in NHPs.¹

Key Applications

NHP models are indispensable for addressing critical questions in infectious disease research:

• Vaccine Challenge & Protection Studies: Evaluate the efficacy of vaccine candidates by challenging vaccinated NHPs with the target pathogen and measuring protection. This includes detailed analysis of seroconversion, neutralizing antibodies, and cell-mediated immunity.
• Antiviral Efficacy and Safety: Assess the effectiveness of novel antiviral drugs by measuring viral load reduction, preventing disease progression, and evaluating potential toxicities in a clinically relevant setting.
• Pathogenesis and Immunopathogenesis: Understand how viruses cause disease and how the host immune system responds. This includes studying viral replication, tropism (which cells the virus infects), and the inflammatory response that can lead to immunopathology.
• Gene and Cell Therapy for Infectious Diseases: Evaluate the safety and biodistribution of viral vectors (e.g., AAV, Lentivirus) and the efficacy of genetically engineered cells (e.g., CAR-T cells) designed to combat chronic or intractable viral infections.

How Do Creative Biolabs Support Your Projects?

Creative Biolabs provides a comprehensive suite of services to support your infectious disease research. We leverage our expertise and state-of-the-art facilities to deliver high-quality, reproducible data that accelerates your path to market.

Translational Impact

Our NHP models provide more reliable early proof of concept for your therapeutic candidates. By accurately mimicking human disease, they allow for the early detection of immune responses and potential toxicity, significantly reducing the risk of costly and time-consuming IND failures. For example, NHP biodistribution and immunogenicity data are often required by regulatory agencies for gene therapy IND submissions, making these studies a non-negotiable step on the path to clinical trials. This proactive approach saves time and resources, while also ensuring a safer, more effective path to patient care.

Frequently Asked Questions

Contact Us

Creative Biolabs is a leader in preclinical research, providing end-to-end solutions for infectious disease studies using clinically relevant NHP models. Our comprehensive platforms, from biological collection to advanced bioanalysis, are designed to accelerate your drug discovery and development timeline. For more information about our NHP applications in infectious diseases or to discuss a specific project, please reach out to our team.